Benzinga··Vandana SinghPraxis Precision Surges on FDA Nod for Essential Tremor Treatment
Praxis Precision shares surge 7.15% after FDA accepts essential tremor drug application with January 2027 decision target and positive Phase 3 results.
PRAXFDA approvalbiotech